For on-demand treatment of acute hereditary angioedema (HAE) attacks
Be prepared for an HAE attack. Be prepared with BERINERT.
BERINERT is the only on-demand treatment offering:
Median onset of laryngeal
attack relief: 15 minutes
Median onset of laryngeal attack relief: 15 minutes
More than 50% of people with HAE may experience a laryngeal attack in their lifetime1
Following self-administration of BERINERT for laryngeal HAE attacks, advise patients to immediately seek medical attention.
In a prospective, randomized, open-label, crossover study, 23 subjects with mild or moderate HAE received a single dose of BERINERT (1000 units) IV or SC during an attack-free interval.2
†BERINERT is the only C1-INH approved for on-demand treatment of acute abdominal, facial or laryngeal attacks of HAE in adults and pediatric patients.
Get your patients started on BERINERT
Prescribe BERINERT and empower them to self-administer at the first sign
of an HAE attack.
Have additional questions?
Connect with CSL Behring Medical Affairs to find additional information and ask questions.
References: 1. Zuraw BL. Clinical practice: hereditary angioedema. N Engl J Med. 2008;359(10):1027-1036.
2. Martinez-Saguer I, Cicardi M, Suffritti C, et al. Pharmacokinetics of plasma-derived C1-esterase inhibitor after subcutaneous versus intravenous administration in subjects with mild or moderate hereditary angioedema: the PASSION study. Transfusion. 2014;54:1552-1561.
3. Nzeako UC, Frigas E, Tremaine WJ. Hereditary angioedema: a broad review for clinicians. Arch Intern Med. 2001;161(20):2417-2429.
4. Bork K, Meng G, Staubach P, et al. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med. 2006;119(3):264-274.